GSK plc (NYSE:GSK) Shares Sold by CarsonAllaria Wealth Management Ltd.

CarsonAllaria Wealth Management Ltd. reduced its stake in GSK plc (NYSE:GSK) by 7.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 3,717 shares of the pharmaceutical company’s stock after selling 289 shares during the period. CarsonAllaria Wealth Management Ltd.’s holdings in GSK were worth $126,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of GSK. FMR LLC raised its stake in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC raised its position in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the period. Primecap Management Co. CA lifted its stake in GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after purchasing an additional 342,365 shares in the last quarter. Provident Trust Co. grew its stake in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after buying an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its holdings in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $34.84 on Wednesday. The stock’s 50-day simple moving average is $34.08 and its 200-day simple moving average is $37.64. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm has a market capitalization of $72.22 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GSK shares. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.